目的：研究d 0,7,14接种程序的乙肝免疫效果方法：无HBV感染和无抗-HBs健康受试者分为组1：军校学员和教师485名,男432女53名；平均年龄27．1(16-58)岁．组2：实习医生和护士234名,男63女171名；平均年龄21．6(18-24)岁．组3：混合人群302名,男170女132；平均年龄29．8(3-69)岁．对照组：高校学生和其他人员383名,男205女178名；平均年龄25．8(2-59)岁．前3组按d 0,7,14程序,对照组按mo 0,1,6程序三角肌内接种乙肝疫苗20μg(＜12岁者10μg)．于首针接种后1,3,7,12,24和36 mo查HBV五项标志、抗-HBs滴度及肝功等．结果：全程接种完成率组1(97．7%)、组2(97．4%)、组3(95．0%)均明显高于对照组(66．3%)(P＜0．001)．对照组中非团体接种171名,43．3%未完成全程接种．首针接种后1,3 mo d 0,7,14程序组血清抗-HBs阳转率分别为66．9%,67．4%,58．2%和96．9%,97．3%,94．0%,明显高于对照组的21．1%和43．1%(P＜0．001)；7 mo时组2仍高于对照组(P＜0．05)．1,3 mo d 0,7,14程序组血清抗-HBs有效保护率分别为63．0%,65．2%,53．0%和94．5%,96．0%,93．6%,显著高于对照组的7．8%和30．9%(P＜0．001)；7和12 mo时对照组高于组3(P＜0．05),组2亦高于组3(P＜0．05)．1,3 mo时d 0,7,14程序组血清抗-HBs几何平均滴度(GMT)分别为122．7%,125．6%,118．8%和131．5%,132．1%,119．3%,显著高于对照组的21．3%和41．5%(P＜0．001)；但7,12,24和36 mo时对照组均高于其他3组(P＜0．05-0．01)．对mo 0,1,6程序无反应者予d 0,7,14(73．1%)方案接种后血清抗-HBs阳转率亦明显高于重复mo 0,1,6(11．0%)方案者(P＜0．001)．结论：d 0,7,14方案操作方便、全程接种完成率高、抗-HBs阳转率和GMT峰值出现早,适用于各类人群,尤需紧急免疫的高危或特殊人群；对0,1,6 mo程序无反应者亦有良好效果． OBJECTIVE: To study the effect of hepatitis B vaccination on d 0,7,14 vaccination procedure: healthy subjects without HBV infection and no anti-HBs were divided into group 1: 485 cadets and teachers, 432 males and 53 females; mean age 27 .1 (16-58) years old. Group 2: 234 intern and nurses, 63 males and 171 females; mean age 21.6 (18-24) years old. Group 3: Mixed population 302, male 170 female 132; average age 29.8 (3-69) years old. Control group: 383 college students and other personnel, 205 males and 178 females; average age 25.8 (2-59) years old. The first three groups according to d 0,7,14 procedures, the control group according to mo 0,1,6 procedures deltoid hepatitis B vaccination 20μg (<12 μg 10μg). Five indexes of HBV, anti-HBs titer, liver function, etc. were examined at 1, 3, 7, 12, 24 and 36 months after the first inoculation. Results: The complete inoculation rate of group 1 (97.7%), group 2 (97.4%) and group 3 (95.0%) were significantly higher than that of control group (66.3%) (P <0.001 ). In the control group, non-group inoculation 171, 43.3% did not complete the full vaccination. The anti-HBs seroconversion rates in the 0, 7, and 14 treatment groups at 1 and 3 mo after the first inoculation were 66.9%, 67.4%, 58.2% and 96.9%, 97.3%, respectively, 94.0%, which was significantly higher than that of the control group (21.1% vs 43.1%, P <0.001); Group 2 was still higher than the control group at 7 months (P <0.05). The effective protection rates of anti-HBs in the 1,3 mo d 0,7,14 program group were 63.0%, 65.2%, 53.0% and 94.5%, 96.0% and 93.6% respectively , Which was significantly higher than 7.8% and 30.9% in the control group (P <0.001). In the control group at 7 and 12 months, it was higher than that in group 3 (P <0.05) (P <0.05). The geometric mean titers (GMTs) of serum anti-HBs at d 0, 7 and 14 at 1,3 mo were 122.7%, 125.6%, 118.8% and 131.5%, 132.1% , 119.3% respectively, which was significantly higher than that of the control group (21.3% vs 41.5%, P <0.001). However, the control group was higher than the other three groups at 7, 12, 24 and 36 months 0.05-0.01). The rate of positive anti-HBs positive after inoculation with d 0,7,14 (73.1%) was also significantly higher than that with repeated mo 0,1,6 (11.0% ) Regimen (P <0.001). Conclusions: d 0, 7 and 14 are easy to operate and have a high vaccination rate and anti-HBs seroconversion rate and GMT peak. They are suitable for all kinds of people, especially at high risk or special population for emergency immunization. Six months of non-responders also had good results.